Proper Dosage of Ketamine in Intravenous Regional Anesthesia

Ketamine

Brief Summary

Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.

Intervention / Treatment

  • Different dosages of Ketamine (DRUG)
    N/A

Condition or Disease

  • Pain.

Phase

  • Not Applicable

    • Study Design

    Study type: INTERVENTIONAL
    Status: Unknown status
    Study results: No Results Available
    Age: 18 Years to 70 Years
    Funded by: Other
    Allocation: Randomized
    Primary Purpose: Treatment

    Masking

    Clinical Trial Dates

    Start date: Jan 01, 2004
    Primary Completion: Aug 31, 2020
    Completion Date: Jan 01, 2005
    Study First Posted: Sep 22, 2005 ESTIMATED
    Results First Posted: Aug 31, 2020
    Last Updated: Oct 10, 2006

    Sponsors / Collaborators

    Lead Sponsor: University Health Network, Toronto
    Responsible Party: N/A
    No responsible party listed

    Location

    Toronto, Ontario, Canada

    Eligibility Criteria

    Sex: All
    Minimum Age: 18
    Maximum Age: 70
    Age Groups: Adult / Older Adult
    Healthy Volunteers: Yes

    Inclusion Criteria:

    1. Age: 18-70
    2. Weight: 50-100 kg
    3. ASA: I, II, III
    4. Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

    Exclusion Criteria:

    1. Contraindication to IVRA such as sickle cell disease.
    2. Any known hypersensitivity reaction to Ketamine.
    3. History of chronic pain or regular medication with analgesics.
    4. History of opioid dependence.
    5. Drug of alcohol abuse.
    6. Psychiatric disorder.
    7. Allergy to acetaminophen or codeine

    More Details

    NCT Number: NCT00221871
    Other IDs: UHN02-0233-A
    Study URL: https://clinicaltrials.gov/study/NCT00221871
    Last updated: Sep 29, 2023